Evidence map›Paper›PMID 37638274›Full record

ReviewCureus2023

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review.

Kiran Prasad Moparthi, Majdah T Al Rushaidi, Meghana Reddy Muddam, Omobolanle A Obajeun, Abdelrahman Abaza, Arturo P Jaramillo, Faten Sid Idris, Humna Anis Shaikh, Ilma Vahora, Tuheen Sankar Nath

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Kiran Prasad MoparthiGeneral Practice, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Majdah T Al RushaidiPsychology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Meghana Reddy MuddamGeneral Practice, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Omobolanle A ObajeunPediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Abdelrahman AbazaPathology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Arturo P JaramilloGeneral Practice, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Faten Sid IdrisPediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Humna Anis ShaikhPediatrics, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Ilma VahoraGeneral Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Tuheen Sankar NathSurgical Oncology, Tata Medical Centre, Kolkata, IND.
Tata Medical Center · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disorders are one of the most frequent causes of death in people throughout the world. These disorders can account for the deaths of 31% of people worldwide. This systematic review examines the effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors in lowering the likelihood of cardiovascular diseases. The study aimed to evaluate various types of research, including randomized controlled trials and observational studies, to analyze how SGLT2 inhibitors impact cardiovascular disorders and establish evidence-based recommendations for clinical practice. The data in this research study were collected from 19 relevant published research articles. The key findings emphasized the potential advantages of SGLT2 inhibitors in reducing major cardiovascular disorders, such as myocardial infarction and stroke. Nonetheless, the study had certain limitations, including reliance on existing literature, exclusion of articles published prior to 2018, and restriction to English-language studies. Despite these limitations, this study contributed significantly to understanding the role of SGLT2 inhibitors in decreasing cardiovascular risk.

Indexed as

cardiovascular disordersmeta-analysisobservational studiessglt2 inhibitorssystematic review

Identifiers

PMID37638274
PMCPMC10457136
OpenAlexW4386127576

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.